Fundz Deep Dive
Everything you need to win Esteve — in one platform.
Who to reach, what to say, and why now on Esteve — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Esteve — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
ESTEVE signs a licensing agreement for Increlex® treatment of severe primary insulin-like growth factor 1 deficiency
Contract Type
agreement
BarcelonaManufacturingBiotechnologyHealth CarePharmaceuticalDescription
ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals for Increlex® with global rights, except for USA. Increlex® is a biologic product used for the long-term treatment of growth failure in patients aged 2 to 18 years due to severe primary insulin-like-growth-factor-1 deficiency (SPIGFD). The medication is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is designated as an 'orphan medicine' for rare diseases.